Novel bright field molecular morphology methods for detection of HER2 gene amplification

Journal of Molecular Histology

Volumn 35, Issue 6, 2004, Pages 589-594

  Tubbs, Raymond ^a   Pettay, James ^a   Hicks, David ^a   Skacel, Marek ^a   Powell, Richard ^c   Grogan, Tom ^b   Hainfeld, James ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Ventana Medical Systems International   (United States)

^c Nanoprobes Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GOLD DERIVATIVE; ISOPROPAMIDE IODIDE; PEROXIDASE; STREPTAVIDIN; METAL;

AUTOMETALLOGRAPHY; BRIGHT FIELD MICROSCOPY; CARCINOMA; CELL INTERACTION; CONFERENCE PAPER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ARTICLE; BREAST TUMOR; CHEMISTRY; CYTOCHEMISTRY; FEMALE; GENETICS; HUMAN; IN SITU HYBRIDIZATION; METHODOLOGY; PROTO ONCOGENE; REPORTER GENE;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, REPORTER; HISTOCYTOCHEMISTRY; HUMANS; IN SITU HYBRIDIZATION; METALS;

EID: 16644396502     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-004-2191-9     Document Type: Conference Paper

References (33)

1. Anttinen JKT, Nykanen M, Torkkeli H, Saari U, Juhola M (2003) Her-2/neu oncogene amplification and protein over-expression in interval and screen detected breast cancers. Anticancer Res 23: 4213-4218.
2. Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J (2003) Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88: 1587-1591.
3. Dandachi N, Dietze O, Hauser-Kronberger C (2002) Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007-1014.
4. Genentech (August 2002) In Herceptin (Trastuzumab) prescribing information.
5. Gupta D, Middleton LP, Whitaker MJ, Abrams J (2003) Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 119: 381-387.
6. Hainfeld JF, Powell RD (2000) New frontiers in gold labeling. J Histochem Cytochem 48: 471-480.
7. Hainfeld JFE, Tubbs RR, Powell RD (2002) In: Voekl EPD, Gauvin R, Lockley AJ, Bailey GW, McKernan S, eds. Enzymatic Metallography: A Simple New Staining Method Vol. 8, Newyork: Cambridge University Press, pp. 916CD.
8. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, Von Smitten K, Lundin J (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1NOMO breast cancer: A nationwide population-based study. Clin Cancer Res 9: 923-930.
9. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82: 1525-1533.
10. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R (2001) Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579-584.
11. Mayer G, Leone RD, Hainfeld JF, Bendayan M (2000) Introduction of a novel HRP substrate-Nanogold probe for signal amplification in immunocytochemistry. J Histochem Cytochem, 48: 461-70.
12. Muller VC, Thomssen et al. (2003) Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 18: 13-20.
13. Palmu S, Soderstrom KO, Quazi K, Isola J, Salminen E (2002) Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 22: 411-414.
14. Park K, Kim J, Lim S, Han S, Lee JY (2003) Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 16: 937-943.
15. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods of tissue-based detection of the HER2/neu alteration in human breast cancer, a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664.
16. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE (2002) HER2 testing in patients with breast cancer: Poor circulation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77: 148-154.
17. Press MF, Hung G, Godolphin W, Slamon DJ (1994) Sensitivity of HER2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777.
18. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of HER2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095-3105.
19. Ratcliffe N, Wells W, Wheeler K, Memoli V (1997) The combination of in situ hybridization and immunohistochemical analysis: An evaluation of HER2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol 10: 1247-1252.
20. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ (2001) Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 81: 1545-1451.
21. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T (2002) Am J Pathol 160: 339-345.
22. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
23. Takahashi M, Inoue K (2003) Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: A case report. Breast Cancer 10: 170-174.
24. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J (2000) Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1467-1472.
25. Tubbs R (2002) Cell markers and cytogenetics committees, college of american pathologists, clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126: 803-808.
26. Tubbs R, Pettay J, Skacel M, Powell R, Stoler M, Roche P, Hainfeld J (2002a) Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ for detection of Her2/neu gene amplification. Am J Pathol 160: 1589-1595.
27. Tubbs R, Skacel M, Pettay J, Powell R, Myles J, Hicks D, Sreenan J, Roche P, Stoler MH, Hainfeld J (2002b) Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol 26: 908-913.
28. Tubbs RR, Pettay J, Roche P, Stoler MH, Jenkins R, Myles J, Grogan T (2000) Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): A fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn 2: 78-83.
29. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19, 2714-2721.
30. Tubbs RR, Stoler MH (2000) Something FISHy? Mod Pathol 13: 1-3.
31. van de Vijver M (2002) Emerging techologies for HER2 testing. Oncology 63(Suppl. 1): 33-38.
32. Zehbe I, Hacker GW, Su H, Hauser-Kronberger C, Hainfeld JF, Tubbs R (1997) Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin-Nanogold, and silver acetate autometallography: Detection of single-copy human papillomavirus. Am J Pathol 150: 1553-1561.
33. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z (2002) Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15: 657-665.